Bioengineering news story
A study, published in Nature Communications, assessed the pharmacokinetics, bactericidal efficacy, and potential toxicities associated with novel short oral treatment regimens for rifampicin-resistant TB.
TB continues to claim millions of lives annually, with rifampicin-resistant strains posing a significant hurdle to global TB control efforts. Rifampicin, a cornerstone antibiotic in first-line TB treatment, loses its efficacy against such resistant strains, necessitating alternative regimens that are not only effective but also feasible and safe for widespread use. The emergence of short-course oral therapies offers hope for spurring higher treatment adherence, reducing adverse events, and potentially curbing transmission rates in high-burden settings.
Read the full news story here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #17, 11 June 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Bioengineering
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.